Kittisak Kaewchalun
- Eli Lilly (NYSE:LLY) said that data from several phase 3 trials of its experimental once-weekly insulin efsitora indicates that it is non-inferior in A1C reduction compared to daily basal insulin.
- In the three trials, QWINT-1, QWINT-3, and QWINT-4, patients enrolled, respectively, used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin.
- Lilly noted that in In QWINT-1, efsitora resulted in about 40% fewer hypoglycemic events compared to insulin glargine. In QWINT-4, estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure were 6.6 with efsitora vs. 5.9 with insulin glargine at 26 weeks.
- The drugmaker said it plans to submit applications for efsitora to global regulatory authorities by the end of the year.
More on Eli Lilly
- Lilly ADA Investor Presentation
- Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association’s (ADA) 85th Scientific Sessions) Conference Transcript
- Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program
- Key deals this week: Couchbase, Eli Lilly, NTT Data, QXO, US Steel and more
- Eli Lilly posts detailed late-stage trial data for oral weight loss drug orforglipron